Stay updated with breaking news from Leukemia service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TG Therapeutics Announces Data Presentations at the globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIALE-A and VIALE-C 1 . The VIALE-A trial demonstrated a statistically significant increase in overall survival with VENCLEXTA in combination with azacitidine compared to azacitidine alone. 1 In the VIALE-C trial, clinical benefit was based on rate and … Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIALE-A (M15-656) and VIALE-C (M16-043) 1 . The VIALE-A trial demonstrated a statistically significant increase in overall survival with VENCLEXTA in combination with azacitidine compared to azacitidine alone. ....